MitrAssist
Minimally Invasive Treatment for Mitral Regurgitation
Company Overview
Snapshot
Founded in April 2009 by Gil Naor, MitrAssist operated with 1–10 employees. The company raised a total of $204 million across 5 funding rounds from 7 investors. In July 2023, MitrAssist secured its Series C funding round, with Centurium Capital and 6.
Business overview
MitrAssist developed a minimally invasive approach to treating mitral regurgitation (MR), a life-threatening heart condition. The company's core technology involves a proprietary valve implant designed to be placed on top of the natural valve, working in unison to enhance its functionality. This valve-in-valve solution aims to overcome existing challenges in MR treatment, offering an alternative for patients. MitrAssist operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving the global healthcare market.
Strategic signal
MitrAssist ceased operations in January 2026, indicating a significant and definitive change in the company's trajectory. This event signals to investors and innovation teams that the company is no longer an active player in the medical device market, despite its prior success in securing substantial funding for its innovative mitral regurgitation treatment.
Log in to access full profile ›Company Intelligence Q&A
- What is MitrAssist's primary focus?
- MitrAssist focuses on developing a minimally invasive treatment for mitral regurgitation (MR) using a proprietary valve implant that works in conjunction with the natural valve to improve its function.
- When did MitrAssist cease operations?
- MitrAssist ceased to operate in January 2026.
- What was the company's last disclosed funding round?
- In July 2023, MitrAssist closed a Series C funding round with Centurium Capital and 6.
- Who founded MitrAssist?
- MitrAssist was founded by Gil Naor in April 2009.
- What is MitrAssist's total funding?
- MitrAssist raised a total of $204 million across 5 funding rounds from 7 investors. The latest round was a Series C in July 2023, with Centurium Capital and 6 Dimension Capital as lead investors.